hVIVO plc HVO
LSE · Birleşik Krallık · Ticari Hizmetler
GBp 6,10+0,05 (+%0,83)
Piyasa kapalı· · GBp · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Piyasa kapalı· · GBp · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Sunda Energy PLC (AIM:SNDA, FRA:GHA0) has raised £5.25 million to fund completion of its New Zealand acquisition. It's also launching a retail offer for a further £525,000. Meridian Mining Plc (LSE:MNO, TSX:MNO, OTCQX:MRRDF) has delivered a net present value of $2.09 billion for its Cabaçal project in Brazil. The CEO says the economics could make it the next major near-term gold-copper mine. Quantum Helium Ltd (AIM:QHE) is targeting Q4 2026 for a larger fracture stimulation programme at Sagebrush-1 in Colorado. It's also taking a 9% stake in Herencia Resources. Light Science Technologies Holdi
Pan African Resources PLC (LSE:PAF, OTCQX:PAFRY, JSE:PAN) has reported record production and earnings for FY2026 after a 40% jump in output. It's now moved from net debt to a "really healthy cash balance." CEO Cobus Loots says its 2027 production target is not a massive stretch. Galliford Try Holdings PLC (LSE:GFRD, FRA:3WC) has delivered a sixth straight year of growth, with profit up 24%. CFO Kris Hampson says the group is well positioned, with a very healthy order book. IP Group PLC (LSE:IPO) has made a strong start to 2026, with NAV per share reaching around 117p. Cash proceeds have alread
hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan spoke with Proactive's Stephen Gunnion about the company's results for the first half of 2026, its record order book, full-year guidance and the expansion of its clinical research services. Khan said hVIVO generated around £16.3 million in revenue in H1, alongside an EBITDA loss of £4.5 million, ending the period with £13 million in cash, a performance in line with the company's previous guidance that 2026 would be weighted towards the second half. A key focus was the order book. Three sizeable human challenge trial contracts, including hVIVO
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.